Developmental toxicity study of glycolic acid in rats.
The developmental toxicity of glycolic acid was assessed in rats by orally administering solutions of the test material in water over days 7-21 of gestation (the day of copulation plug detection was defined as day 1 of gestation). Groups of 25 mated female Crl: CD BR rats were gavaged at daily dose levels of 0, 75, 150, 300 or 600 mg/kg. The dams were euthanized on day 22 and the offspring were weighed, sexed, and examined for external, visceral, and skeletal alterations. Clear evidence of maternal toxicity was demonstrated at 600 mg/kg; adverse clinical observations were statistically significantly increased (wheezing/lung noise, abnormal gait/staggering, lethargy). In addition, maternal body weights, weight changes, and food consumption were statistically significantly reduced at this dose level. Marginal evidence of maternal toxicity was demonstrated at 300 mg/kg; wheezing/lung noise similar to that seen at 600 mg/kg was observed in 2 of 25 dams. This increase approached statistical significance (p = 0.0553). There was marked evidence of developmental toxicity at 600 mg/kg. Mean fetal weight was statistically significantly reduced while the incidences of skeletal (ribs, vertebra, and sternebra) malformations and variations were statistically significantly increased. At 300 mg/kg/day, there was a slight (2 affected fetuses from 2 litters) increase in the incidence of two skeletal malformations: fused ribs and fused vertebra. Although these increases were not statistically significant (p = 0.0555), they were consistent with findings seen at 600 mg/kg/day and thus were considered relevant. There was no other evidence of developmental toxicity at 300 mg/kg/day nor was any developmental toxicity seen at 150 or 75 mg/kg/day. Thus, the maternal and developmental no-observed-effect level (NOEL) was considered 150 mg/kg.
Munley
S M
SM
Haskell Laboratory for Toxicology and Industrial Medicine, E. I. du Pont de Nemours, Inc., Newark, Delaware, USA.
Kennedy
G L
GL
Hurtt
M E
ME
D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000473:pathology; D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001842:Bone and Bones / Q000002:abnormalities*; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D005260:Female; D005333:Fetus / Q000002:abnormalities / Q000187:drug effects; D006016:Glycolates / Q000008:administration & dosage / Q000633:toxicity*; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D011247:Pregnancy; D051381:Rats; D012098:Reproduction / Q000187:drug effects
D006016:Glycolates; D007641:Keratolytic Agents; C031149:glycolic acid